Szarc Vel Szic et al. [73] showed that withaferin A (WA) downregulated HER2/PR/ESR-dependent gene expression interactions and thus repressed aggressive triple-negative MDA-MB-231 breast cancer cells with a specific DNA hypomethylation profile. Here, ESR1 is linked to breast carcinoma.